A Study of Surgery and Radiotherapy in People With Breast Cancer
The researchers are doing this study to see if the combination of surgery, locoregional radiation therapy, SBRT (stereotactic body radiation therapy), and the usual approach is more effective in treating oligometastatic HER2-positive breast cancer than the usual approach alone. The researchers will also study the side effects of the study treatment.
Conditions studied
Metastatic Breast Cancer, HER2-positive Breast Cancer
About this study
The researchers are doing this study to see if the combination of surgery, locoregional radiation therapy, SBRT (stereotactic body radiation therapy), and the usual approach is more effective in treating oligometastatic HER2-positive breast cancer than the usual approach alone. The researchers will also study the side effects of the study treatment.
Interventions
- Procedure: Lumpectomy or mastectomy — Resection of the primary breast tumor (ie. lumpectomy when possible or mastectomy when breast conservation not possible). Surgical resection of the primary breast tumor is to be performed per standard guidelines as applied to localized disease. Breast conserving surgery (ie. lumpectomy) is allowable per patient preference when supported by standard surgical practice. Mastectomy is preferred when breast conservation is declined by the patient, or if breast conservation would otherwise not be feasible in the early-stage setting (e.g. large tumor:breast volume ratio, inability to achieve negative margins with breast conservation, etc)
- Radiation: Radiotherapy — Radiotherapy will be delivered using external beam radiation per the guidelines.Radiotherapy will be delivered using external beam radiation per the guidelines set forth below, targeting two main compartments: 1. Patients will undergo radiotherapy to the breast/chest wall, and regional nodal basins (including the axilla, supraclavicular fossa and internal mammary chain) per the standard adjuvant approach for locally advanced disease, and 2. Patient will undergo stereotactic body radiotherapy (SBRT) or similarly-ablative approaches to sites of distant disease, including all observable foci and those that may have since resolved radiographically during systemic therapy
- Drug: Trastuzumab, Pertuzumab, Paclitaxel, or a combination of these drugs — Continue to receive the standard treatment you have already started, which includes trastuzumab, pertuzumab, paclitaxel, or a combination of these drugs. This treatment is not part of the study and will be decided by your regular treating physician.
Primary outcomes
- Progression-free survival (PFS) (3 years)
Eligibility information
Study locations
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey 07920 United States
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey 07748 United States
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey 07645 United States
- Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities ), Commack, New York 11725 United States
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York 10604 United States
- Memorial Sloan Kettering Cancer Center (All protocol activites), New York, New York 10065 United States
- Memorial Sloan Kettering Nassau (Limited protocol activities), Rockville Centre, New York 11553 United States
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-11-17.